Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » PCR » Xprize Announces 20 Finalists in $6M Rapid COVID-19 Testing Competition

Xprize Announces 20 Finalists in $6M Rapid COVID-19 Testing Competition

Dec 22, 2020
|
staff reporter

NEW YORK ─ Xprize on Tuesday announced 20 finalists in a $6 million rapid COVID-19 testing competition that aims to facilitate the development of rapid tests and accelerate the safe return to public spaces.

Culver City, California-based Xprize said it selected finalist teams from 219 semifinalists after conducting blind proficiency testing and judging a detailed questionnaire reflecting each team's qualifications.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Areas of Limited Testing

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

Clouded 'Crystal Ball'

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

Million a Day

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

Science Papers Trace Drivers of Metastasis; Genetic Analysis of Stone, Bronze Age Eastern Europeans

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.

Feb
11
Featured Webinar

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
25
Featured Webinar

Virtual Molecular Tumor Board Series: Common Driver Mutations in ‘Off-Label’ Tumor Types

Sponsored by
Foundation Medicine

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
25
Featured Webinar

Virtual Molecular Tumor Board Series: What to Do with a ‘Negative’ Molecular Panel Case

Sponsored by
Foundation Medicine

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.

What's Popular?

In Point-of-Care Testing

  1. Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.